Connectivity and Remote Care for Heart Failure Management

With remote monitoring, you can gain critical information about your patient's cardiac health and heart failure progression. This connection with your patients allows you to intervene early and provide your patients with the personalized care they deserve. Learn how our connectivity and remote care devices can lead to better heart failure management.

CardioMEMS HF System and the Patient Care Network (PCN)

The CardioMEMS™ HF System is a pulmonary artery (PA) pressure monitoring system clinically proven to aid physicians in preventing worsening heart failure,1 lowering mortality rates2 and improving quality of life3,4 — even for HFpEF patients.5 The CardioMEMS HF System sends patient data to the™ Patient Care Network (PCN), so healthcare professionals have access to patients’ data transmissions via a secure website. PCN presents PA pressure data as actionable information to guide earlier, more appropriate intervention for each patient.

Heart Failure Management Powered by Remote Hemodynamic Monitoring

What if you knew your heart failure patient’s current hemodynamic data before making treatment decisions?

Imagine how your heart failure treatment plan would change if you had remote access to your patient’s:

  • Preload status (RAM, PCWP)
  • Afterload status (SVR, PVR)
  • Pulmonary hypertension status (PAM, PVR)

Hemodynamic Data is Essential to Inform Personalized Heart Failure Management

The pulmonary artery (PA) is the only anatomical location in the body that provides hemodynamic data on both the right and left sides of the heart. With the CardioMEMS HF System, you can remotely monitor your patient’s PA pressure — all while they are living their life outside of the hospital.

The CardioMEMS PA Sensor is implanted during a standard RHC procedure, giving you the baseline RHC data to inform treatment strategy when used remotely with real-time PA pressures as a guide.

Hemodynamic monitoring can help you optimize individualized GDMT and prevent disease progression.

Manuals & Technical Resources

Manuals & Technical Resources

Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service


  1. Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
  2. Abraham J, Jonsson O, Oliveira G, et al. Lower Mortality and Heart Failure Hospitalization Rates in Patients Implanted with Pulmonary Artery Pressure Sensor – A Real-world Comparative Effectiveness Study (2018) Presented at the 67th Annual Scientific Sessions of the American College of Cardiology. JACC. 2018;71(11 Supplement):A311.7.
  3. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.5.
  4. Angermann, C.E., Assmus, B., Anker, S.D. et al. Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clin Res Cardiol 107, 991–1002 (2018).
  5. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2014;7(6):935-944.


Indications, Safety & Warnings

CardioMEMS HF System

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

CardioMEMS™ HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

CardioMEMS™ HF System Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS™ HF System Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.

myCardioMEMS™ Mobile App Limitations: Patients must use their own Apple or Android mobile device to receive and transmit information to the myCardioMEMS Mobile App. To do so the device must be powered on, app must be installed and data coverage (cellular or Wi-Fi) available. The myCardioMEMS App can provide notification of medication adjustments and reminders, requests for lab work and acknowledgement that the PA pressure readings have been received. However there are many internal and external factors that can hinder, delay, or prevent acquisition and delivery of the notifications and patient information as intended by the clinician. These factors include: patient environment, data services, mobile device operating system and settings, clinic environment, schedule/configuration changes, or data processing.

MAT-2006720 v2.0